Last $117.60 USD
Change Today +12.41 / 11.80%
Volume 1.8M
As of 12:21 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

edwards lifesciences corp (EW) Snapshot

Open
$113.50
Previous Close
$105.19
Day High
$117.94
Day Low
$113.22
52 Week High
10/24/14 - $117.63
52 Week Low
12/13/13 - $60.62
Market Cap
12.5B
Average Volume 10 Days
1.0M
EPS TTM
$2.83
Shares Outstanding
106.0M
EX-Date
--
P/E TM
41.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for EDWARDS LIFESCIENCES CORP (EW)

edwards lifesciences corp (EW) Related Businessweek News

No Related Businessweek News Found

edwards lifesciences corp (EW) Details

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers surgical heart valve therapy products, such as tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve; and produces pericardial valves from biologically inert animal tissue. Its surgical heart valve therapy products include Carpentier-Edwards PERIMOUNT pericardial valve that comprise PERIMOUNT Magna Ease valves for aortic and mitral replacement; ThruPort systems that enable minimal incision valve surgery; and protection cannulae that is used during cardiac surgery in venous drainage, aortic perfusion, venting, and cardioplegia delivery. The company also provides transcatheter heart valves portfolio that includes technologies designed to treat heart valve disease using catheter-based approaches, as well as critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; Swan-Ganz line of pulmonary artery and PreSep continuous venous oximetry catheters for measuring central venous oxygen saturation; VolumeView sensor-catheters; FloTrac continuous cardiac output monitoring system, a minimally invasive cardiac monitoring technology for fluid optimization; and EV1000 clinical monitoring platform, which displays a patient's physiologic status. Its critical care products also include disposable pressure monitoring devices and closed blood sampling systems to help protect patients and clinicians from the risk of infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as balloon-tipped, catheter-based embolectomy products, surgical clips, and clamps. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

8,600 Employees
Last Reported Date: 02/28/14
Founded in 1999

edwards lifesciences corp (EW) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $879.8K
Corporate Vice President of Europe, Middle Ea...
Total Annual Compensation: $607.8K
Corporate Vice President of Heart Valve Thera...
Total Annual Compensation: $440.6K
Compensation as of Fiscal Year 2013.

edwards lifesciences corp (EW) Key Developments

Edwards Lifesciences Corp. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Raises Earnings Guidance for the Fourth Quarter and Full Year of 2014

Edwards Lifesciences Corp. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net income of $94.6 million, or $0.87 per diluted share compared to net income of $76.8 million, or $0.68 per diluted share for the same period in 2013. Net sales were $607.5 million against $495.6 million a year ago. Income before provision for income taxes was $120.6 million against $99.8 million for the same period last year. Net cash flow from operating activities was $12.2 million against $132.2 million a year ago. Non-GAAP net income was $87.0 million or $0.80 per diluted share compared to net income of $79.5 million or $0.70 per diluted share for the same period in 2013. Capital expenditures were $18.1 million against $22.6 million a year ago. For the nine months, the company recorded net income of $701.9 million, or $6.49 per diluted share compared to $314.0 million or $2.74 per diluted share for the same period in 2012. Net sales were $1,704.9 million against $1,509.5 million a year ago. Income before provision for income taxes was $1,011.1 million against $410.9 million for the same period last year. Non-GAAP net income was $263.1 million or $2.43 per diluted share compared to net income of $262.9 or $2.294 per diluted share for the same period in 2013. Net cash flow from operating activities was $929.1 million against $361.4 million a year ago. Capital expenditures were $48.4 million against $88.9 million a year ago. For the full year of 2014, the company expects total sales to exceed the high end of its previous $2.05 billion to $2.25 billion range.  The company also raised its guidance for full year 2014 diluted earnings per share, excluding special items, to a range of $3.33 to $3.39.  For the fourth quarter of 2014, the company projects total sales to be between $575 million and $615 million, and diluted earnings per share, excluding special items, to be between $0.89 and $0.95. The effective tax rate will drop to approximately 16% in the fourth quarter, assuming renewal of the federal research and development tax credit.

Edwards Lifesciences Corp. Announces Resignation of Carlyn D. Solomon as Corporate Vice President

Edwards Lifesciences Corp. announced that Carlyn D. Solomon tendered his resignation from his position as Corporate Vice President, Critical Care and Vascular of the company on October 3, 2014, in order to accept the position of chief operating officer at another medical products company. Solomon currently intends to remain with the Company during a brief transition period.

Edwards Lifesciences Corp. to Report Q3, 2014 Results on Oct 23, 2014

Edwards Lifesciences Corp. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Standard Time on Oct 23, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EW:US $117.60 USD +12.41

EW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $157.56 USD +3.33
Endo International PLC $64.80 USD +0.14
Hologic Inc $24.90 USD +0.125
Mettler-Toledo International Inc $251.87 USD +1.58
Cooper Cos Inc/The $157.28 USD +1.15
View Industry Companies
 

Industry Analysis

EW

Industry Average

Valuation EW Industry Range
Price/Earnings 15.2x
Price/Sales 5.2x
Price/Book 5.8x
Price/Cash Flow 14.6x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit www.edwards.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.